Gene Therapy Experiment Aims to Combat Glaucoma Through Cellular Regeneration
Boston-based company, Laf Bousaensys, has initiated the first phase of a gene therapy experiment targeting glaucoma, utilizing media-based treatment. The “Neychr” publication reported that this initial intervention, part of a planned 12-patient clinical trial, focused on activating specific genes within the optic nerve. The experiment, conducted at SAZ, seeks to stimulate neuron regeneration in the optic nerve, a key component of vision and frequently damaged in glaucoma cases.
Researchers aimed to activate three genes believed capable of promoting this regeneration. Laf Bousaensys anticipates expanding the therapy’s potential to address non-arteritic anterior ischemic optic neuropathy (NAION), a condition which can lead to optic nerve death and vision loss. The primary goal of which is to restore the function of the affected optic nerve.
This initial experiment represents a crucial step in the development of this novel therapy. The company’s long-term objective is to refine the treatment and ultimately offer a solution for patients suffering from optic nerve damage.
Topics: #which #therapy #experiment
This innovative approach to treating glaucoma in young patients offers a potentially groundbreaking solution.
What is the potential long-term impact of this cellular regeneration therapy on patients with glaucoma?